February 19, 2021

IBRI RESEARCH PUBLISHED: Pro-Inflammatory Cytokines Induce Insulin and Glucagon Double Positive Human Islet Cells That Are Resistant to Apoptosis

Abstract The presence of islet cells double positive for insulin and glucagon (Ins + /Glu + ) has been described in the pancreas from both type 2 (T2D) and...

January 28, 2021

IBRI IN THE NEWS: IBRI Researchers Find Opportunity to Repurpose Drugs for Type 1 Diabetes

More than 7% of Americans suffer from debilitating and, in some cases, life-threatening autoimmune diseases. With diagnoses on the rise, researchers continue the quest for more effective treatments and the...

January 07, 2021

IBRI RESEARCH PUBLISHED: Gene Expression Signatures of Target Tissues in Type 1 Diabetes, Lupus Erythematosus, Multiple Sclerosis, and Rheumatoid Arthritis

Abstract Autoimmune diseases are typically studied with a focus on the immune system, and less attention is paid to responses of target tissues exposed to the immune assault. We...

January 06, 2021

A New Approach to Study Autoimmune Diseases

Indianapolis, Ind. - A team of researchers led by the Indiana Biosciences Research Institute Diabetes Center’s Scientific Director Decio L. Eizirik, MD, PhD, has found that identifying new treatments for...

December 29, 2020

IBRI RESEARCH PUBLISHED: The RNA-binding Profile of the Splicing Factor SRSF6 in Immortalized Human Pancreatic ß-cells

Abstract In pancreatic β-cells, the expression of the splicing factor SRSF6 is regulated by GLIS3, a transcription factor encoded by a diabetes susceptibility gene. SRSF6 down-regulation promotes β-cell demise...

December 01, 2020

IBRI RESEARCH PUBLISHED: Persistent or Transient Human ß Cell Dysfunction Induced by Metabolic Stress: Specific Signatures and Shared Gene Expression with Type 2 Diabetes

Abstract Pancreatic β cell failure is key to type 2 diabetes (T2D) onset and progression. Here, we assess whether human β cell dysfunction induced by metabolic stress is reversible,...

November 20, 2020

IBRI RESEARCH PUBLISHED: Integration of single-cell datasets reveals novel transcriptomic signatures of ß-cells in human T2D

Abstract Pancreatic islet β-cell failure is key to the onset and progression of type 2 diabetes (T2D). The advent of single-cell RNA sequencing (scRNA-seq) has opened the possibility to...

November 16, 2020

IBRI RESEARCH PUBLISHED: Enzyme Immunoassay-Based Platform for Accurate Detection of Serum Pathological a-Synuclein in Parkinson’s Disease Patients

Abstract An assay for accurately diagnosing early stage Parkinson’s Disease (PD) is currently unavailable, and therefore, there is an urgent and unmet need. Such a diagnostic assay will enable...

November 12, 2020

IBRI IN THE NEWS: Biosciences Research Institute Adds Board Members

The Indiana Biosciences Research Institute has added eight members to its board of directors, including Bob Bernhard (pictured) and Wendy Srnic (pictured). Bernhard serves as vice president for research at...

November 11, 2020

IBRI RESEARCH PUBLISHED: YIPF5 Mutations Cause Neonatal Diabetes and Microcephaly through Endoplasmic Reticulum Stress

Abstract Neonatal diabetes is caused by single gene mutations reducing pancreatic β cell number or impairing β cell function. Understanding the genetic basis of rare diabetes subtypes highlights fundamental...

 1 2 3 4 5  ... Last 
2019 Annual Report cover

The IBRI 2019 Annual Report is now available. The report theme is “Catalyze, Complement, Connect,” which correlates with the IBRI's goals to seek solutions for health problems, enhance the Indiana life sciences ecosystem, and expedite solutions for the most pressing health issues.